中国肝癌多学科综合治疗专家共识（2025年版）

中国抗癌协会肝癌专业委员会

doi:10.12449/JCH250709

中国肝癌多学科综合治疗专家共识（2025年版）

DOI: 10.12449/JCH250709

中国抗癌协会肝癌专业委员会

利益冲突声明：所有作者均声明不存在利益冲突。

计量
- 文章访问数: 2271
- HTML全文浏览量: 494
- PDF下载量: 1213
- 被引次数: 0
出版历程
- 收稿日期: 2025-07-03
- 录用日期: 2025-07-05
- 出版日期: 2025-07-25

Chinese expert consensus on multidisciplinary treatment of liver cancer（2025）

Chinese Society of Liver Cancer， Chinese Anti-Cancer Association

摘要

- 肝肿瘤 /
- 治疗学 /
- 共识
- Liver Neoplasms /
- Therapeutics /
- Consensus

HTML全文

注： HCC，肝细胞癌：PS，体力活动状态；TACE，经导管动脉化疗栓塞术；AFP，甲胎蛋白。系统抗肿瘤治疗包括一线治疗，即阿替利珠单抗＋贝伐珠单抗、信迪利单抗＋贝伐珠单抗类似物、甲磺酸阿帕替尼＋卡瑞利珠单抗、多纳非尼、仑伐替尼、替雷利珠单抗、索拉非尼、FOLFOX4。二线治疗为瑞戈非尼、阿帕替尼、雷莫西尤单抗（血清AFP水平≥400 μg/L）、帕博利珠单抗、卡瑞利珠单抗、替雷利珠单抗。

图 1 中国肝癌临床分期与治疗路线图^［3］

Figure 1. China liver cancer clinical staging and treatment roadmap^［3］

下载: 全尺寸图片幻灯片

注： ALPPS，联合肝脏分隔和门静脉结扎的二步肝切除术；PVE，门静脉栓塞术；MVI，微血管侵犯。

图 2 肝癌转化及围手术期治疗路线^［6］

Figure 2. Liver cancer conversion and perioperative treatment roadmap^［6］

下载: 全尺寸图片幻灯片

参考文献(40)

[1]	ZHENG RS, ZHANG SW, ZENG HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2( 1): 1- 9. DOI: 10.1016/j.jncc.2022.02.002.
[2]	ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
[3]	National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
[4]	Society of Liver Cancer, Guangdong Provincial Anti-cancer Association. Establishment of multi-disciplinary team for comprehensive treatment of liver cancer-consensus of experts in Guangdong, China(1)[J]. J Clin Hepatol, 2014, 30( 11): 1112- 1115. DOI: 10.3969/j.issn.1001-5256.2014.11.004. 广东省抗癌协会肝癌专业委员会. 肝癌多学科综合治疗团队建立——广东专家共识(1)[J]. 临床肝胆病杂志, 2014, 30( 11): 1112- 1115. DOI: 10.3969/j.issn.1001-5256.2014.11.004.
[5]	Society of Liver Cancer, Guangdong Provincial Anti-cancer Association. Strategy and method of multi-disciplinary comprehensive treatment of liver cancer-consensus of experts in Guangdong, China(2)[J]. J Clin Hepatol, 2014, 30( 11): 1116- 1119. DOI: 10.3969/j.issn.1001-5256.2014.11.005. 广东省抗癌协会肝癌专业委员会. 肝癌多学科联合治疗策略与方法——广东专家共识(2)[J]. 临床肝胆病杂志, 2014, 30( 11): 1116- 1119. DOI: 10.3969/j.issn.1001-5256.2014.11.005.
[6]	Chinese Society of Clinical Oncology(CSCO) Guidelines Committee. Guidelines of Chinese society of clinical oncology(CSCO) hepatocellular carcinoma[M]. Beijing: People’s Medical Publishing House, 2024. 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南2024[M]. 北京: 人民卫生出版社, 2024.
[7]	JIA WD. Multidisciplinary treatments for patients with hepatocellular carcinoma in the era of precise liver surgery[J]. J Pract Hepatol, 2015, 18( 2): 120- 123. DOI: 10.3969/j.issn.1672-5069.2015.02.004. 荚卫东. 精准肝脏外科时代肝癌多学科治疗[J]. 实用肝脏病杂志, 2015, 18( 2): 120- 123. DOI: 10.3969/j.issn.1672-5069.2015.02.004.
[8]	CHEN MS, LI JQ, ZHENG Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006, 243( 3): 321- 328. DOI: 10.1097/01.sla.0000201480.65519.b8.
[9]	FENG K, YAN J, LI XW, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012, 57( 4): 794- 802. DOI: 10.1016/j.jhep.2012.05.007.
[10]	PENG ZW, LIN XJ, ZHANG YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: A retrospective comparative study[J]. Radiology, 2012, 262( 3): 1022- 1033. DOI: 10.1148/radiol.11110817.
[11]	XU QH, KOBAYASHI S, YE X, et al. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: A meta-analysis of 16, 103 patients[J]. Sci Rep, 2014, 4: 7252. DOI: 10.1038/srep07252.
[12]	LIVRAGHI T, MELONI F, di STASI M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?[J]. Hepatology, 2008, 47( 1): 82- 89. DOI: 10.1002/hep.21933.
[13]	PENG ZW, ZHANG YJ, CHEN MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial[J]. J Clin Oncol, 2013, 31( 4): 426- 432. DOI: 10.1200/JCO.2012.42.9936.
[14]	ZHANG YJ, CHEN JB, ZHOU ZG, et al. Transarterial chemoembolization with radiofrequency ablation versus surgical resection for small late-recurrence hepatocellular carcinoma[J]. Radiology, 2025, 314( 2): e241096. DOI: 10.1148/radiol.241096.
[15]	PAN YX, XI M, FU YZ, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: A retrospective propensity score matching study[J]. Cancers(Basel), 2019, 11( 8): 1116. DOI: 10.3390/cancers11081116.
[16]	XI M, YANG ZT, HU L, et al. Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, open-label, controlled trial[J]. J Clin Oncol, 2025, 43( 9): 1073- 1082. DOI: 10.1200/JCO-24-01532.
[17]	WEI W, JIAN PE, LI SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: A randomized clinical trial of efficacy and safety[J]. Cancer Commun(Lond), 2018, 38( 1): 61. DOI: 10.1186/s40880-018-0331-y.
[18]	LI SH, MEI J, CHENG Y, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: A multicenter, phase III, randomized study[J]. J Clin Oncol, 2023, 41( 10): 1898- 1908. DOI: 10.1200/JCO.22.01142.
[19]	OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11( 4): 317- 370. DOI: 10.1007/s12072-017-9799-9.
[20]	METUSSIN A, PATANWALA I, CROSS TJ. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT[J]. J Hepatol, 2015, 62( 3): 747- 748. DOI: 10.1016/j.jhep.2014.08.057.
[21]	ZHONG JH, KE Y, GONG WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260( 2): 329- 340. DOI: 10.1097/SLA.0000000000000236.
[22]	ZHOU C, PENG YF, ZHOU KQ, et al. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2019, 8( 1): 19- 28. DOI: 10.21037/hbsn.2018.11.19.
[23]	YAN J, MAN ZS, LU Q, et al. Long-term survival in patients receiving combination therapy with resection and radiofrequency ablation for multi-focal hepatocellular carcinoma classified as Barcelona clinic liver cancer stage B: A retrospective controlled study[J]. Cancer Manag Res, 2020, 12: 2613- 2621. DOI: 10.2147/CMAR.S237635.
[24]	PENG WY, CHEN JQ, LIU CW, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J]. Cancer Discov, 2016, 6( 2): 202- 216. DOI: 10.1158/2159-8290.CD-15-0283.
[25]	Chinese College of Interventionalists. Chinese Medical Doctor Association. Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. J Intervent Radiol, 2018, 27( 12): 1117- 1126. DOI: 10.3969/j.issn.1008-794X.2018.12.001. 中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 介入放射学杂志, 2018, 27( 12): 1117- 1126. DOI: 10.3969/j.issn.1008-794X.2018.12.001.
[26]	CHEN QW, YING HF, GAO S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016, 40( 3): 309- 314. DOI: 10.1016/j.clinre.2015.07.008.
[27]	KUDO M. A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: Initial lenvatinib therapy with subsequent selective TACE[J]. Liver Cancer, 2019, 8( 5): 299- 311. DOI: 10.1159/000502905.
[28]	CHENG SQ, WU MC, CHEN H, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54( 74): 499- 502.
[29]	XUE TC, XIE XY, ZHANG L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis[J]. BMC Gastroenterol, 2013, 13: 60. DOI: 10.1186/1471-230X-13-60.
[30]	HE MK, LI QJ, ZOU RH, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5( 7): 953- 960. DOI: 10.1001/jamaoncol.2019.0250.
[31]	ZHU KS, CHEN JW, LAI LS, et al. Hepatocellular carcinoma with portal vein tumor thrombus: Treatment with transarterial chemoembolization combined with sorafenib: A retrospective controlled study[J]. Radiology, 2014, 272( 1): 284- 293. DOI: 10.1148/radiol.14131946.
[32]	Radiation Oncology Branch of the Chinese Medical Association Expert Committee on Liver Cancer and Digestive System of China Institute of Biomedical Engineering Liver Cancer Research Group of Radiation Oncology Branch of China Research Hospital. Consensus on radiation therapy for primary liver cancer in 2016[J]. Chin J Rad Oncol, 2016, 25( 11): 1141- 1150. DOI: 10.3760/cma.j.issn.1004-4221.2016.11.001. 中华医学会放射肿瘤学分会, 中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会, 中国研究型医院学会放射肿瘤学分会肝癌学组. 2016年原发性肝癌放疗共识[J]. 中华放射肿瘤学杂志, 2016, 25( 11): 1141- 1150. DOI: 10.3760/cma.j.issn.1004-4221.2016.11.001.
[33]	SUN JX, YANG L, SHI J, et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140: 20- 25. DOI: 10.1016/j.radonc.2019.05.006.
[34]	ZHANG HG, CHEN YX, HU Y, et al. Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma[J]. Ann Palliat Med, 2019, 8( 5): 717- 727. DOI: 10.21037/apm.2019.11.17.
[35]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. J Pract Hepatol, 2023, 26( 3): S18- S39. DOI: 10.3969/j.issn.1672-5069.2023.03.040. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26( 3): S18- S39. DOI: 10.3969/j.issn.1672-5069.2023.03.040.
[36]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[37]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010. 中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35( 6): 1222- 1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010.
[38]	National Health Commission of the People’s Republic of China. Standard diagnosis and treatment of cancer pain(version 2018)[J]. Chin Clin Oncol, 2018, 23( 10): 937- 944. 中华人民共和国国家卫生健康委员会. 癌症疼痛诊疗规范(2018年版)[J]. 临床肿瘤学杂志, 2018, 23( 10): 937- 944.
[39]	KUMAR M, PANDA D. Role of supportive care for terminal stage hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2014, 4( Suppl 3): S130- S139. DOI: 10.1016/j.jceh.2014.03.049.
[40]	SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: Outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14( 4): 203- 217. DOI: 10.1038/nrgastro.2016.193.